Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 38

Results For "DoP"

445 News Found

Union Budget 2022-23 : Industry expects increased allocation to healthcare, skill development, R&D and universal health insurance
Hospitals | January 30, 2022

Union Budget 2022-23 : Industry expects increased allocation to healthcare, skill development, R&D and universal health insurance

Allocation for the healthcare sector has gone up but is still woefully short of expectations. A few leading voices from the hospital and consulting sectors share their perspective on what they expect from Budget 2022


Dr Reddy’s Q3FY22 PAT at Rs. 706 cr.
News | January 28, 2022

Dr Reddy’s Q3FY22 PAT at Rs. 706 cr.

Dr. Reddy's Laboratories has reported consolidated financial results for the period ended December 31, 2021


Mandaviya reviews public health preparedness to Covid-19
Policy | January 26, 2022

Mandaviya reviews public health preparedness to Covid-19

Urges them to focus on tele-consultation like eSanjeevani and efficient monitoring of those in home isolation


RaphaCure partners with Madhavbaug for cardiac healthcare services
Diagnostic Center | January 24, 2022

RaphaCure partners with Madhavbaug for cardiac healthcare services

Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals


We plan to move to other geographies as we expand: Jeya Kumar, Founder and MD, RaphaCure
interviews | January 17, 2022

We plan to move to other geographies as we expand: Jeya Kumar, Founder and MD, RaphaCure

The tele-heath market in India is expected to touch US $ 5.4 billion by 2025 and the adoption of tele-health has accelerated with the onset of Covid-19 in 2020. We caught up with Jeya Kumar, Founder and MD, RaphaCure, a prominent player in this segment and he outlined the opportunities that lie ahead for this segment


Green Valley receives US FDA approval for Phase II clinical trial for Parkinson’s disease
Biotech | January 17, 2022

Green Valley receives US FDA approval for Phase II clinical trial for Parkinson’s disease

The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period


SeQuent Scientific appoints Rajaram Narayanan as MD & CEO
People | January 17, 2022

SeQuent Scientific appoints Rajaram Narayanan as MD & CEO

Narayanan to lead SeQuent through next phase of consolidation and growth


AIIMS now uses ImmersiveTouch for surgeries
Digitisation | January 14, 2022

AIIMS now uses ImmersiveTouch for surgeries

Chicago based virtual reality company reaches AIIMS, assisting in surgical planning and training


Roche introduces cobas infinity edge
Medical Device | January 11, 2022

Roche introduces cobas infinity edge

Cobas infinity edge is designed as an open platform, allowing healthcare professionals to easily access and adopt third-party innovators’ new digital tools and medically-relevant applications via the Roche digital marketplace


Intuitive India launches Intuitive Telepresence for remote surgical case observation
Digitisation | January 11, 2022

Intuitive India launches Intuitive Telepresence for remote surgical case observation

Intuitive Telepresence (ITP), facilitates remote learning, and encourages interaction and collaboration between surgeons without the need to travel